drugset / Trial / NCT00328497
A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This single center, open-label study will evaluate the safety and efficacy of Panzem (2-methoxyestradiol, 2ME2) Nanocrystal Dispersion (NCD) administered orally with recombinant human monoclonal antibody against vascular endothelial growth factor (bevacizumab) administered intravenously, in patients with locally advanced or metastatic carcinoid tumors.
Timeline
- Start
- 2006-05
- Primary completion
- 2008-12
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 2-methoxyestradiol | Small molecule | 1000 mg | Oral |
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |